Search SBFMW
Sunshine Biopharma Inc.
Nasdaq, Nasdaq · CIK 1402328
Last close0.03
Daily change-0.03 (-52.10%)
10 Years gain-70.51%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SBFMW · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
49.5Momentum
38.5Acceleration
38.5Confidence
82.0Annual Revenue16
Quarterly Revenue60
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.6 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.5363 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 2.3081 percentage points.
Key Metrics
Revenue Growth TTM5.85%OK
Revenue CAGR 3Y102.91%OK
Gross Margin30.69%OK
Operating Margin-17%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-34.25%OK
Incremental Operating Margin 3Y65.5%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $36.31M | $12.26M | -$6.23M | -$5.33M | -$5.51M | 33.76% | -17.15% | -15.16% | -35.48% | n/a |
| 2025 FY Dec 31, 2024 | $34.87M | $10.67M | -$5.81M | -$12.52M | -$14.18M | 30.6% | -16.67% | -40.67% | -49.03% | n/a |
| 2024 FY Dec 31, 2023 | $24.09M | $8.34M | -$4.79M | -$8.78M | -$8.86M | 34.61% | -19.86% | -36.76% | -160.32% | 12,825 |
| 2023 FY Dec 31, 2022 | $4.35M | $1.70M | -$27.00M | -$5.25M | -$5.44M | 39.04% | -621.33% | -125.24% | n/a | 15.18M |
| 2022 FY Dec 31, 2021 | $228,426.00 | $110,596.00 | -$2.44M | -$1.83M | -$1.83M | 48.42% | -1,068.24% | -800.75% | n/a | 2.61M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $36.18M | sum latest 4 fiscal quarters Revenue | OK | 0001683168-26-006340, 0001683168-25-008328 |
| Revenue Growth TTM | 5.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001683168-26-006340, 0001683168-25-008328 |
| Revenue CAGR 3Y | 102.91% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-002644 |
| Revenue CAGR 5Y | 247.73% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001683168-26-002644 |
| Gross Profit CAGR 3Y | 93.31% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-002644 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001683168-26-006340, 0001683168-25-008328 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 30.69% | Gross Profit / Revenue | OK | 0001683168-26-006340, 0001683168-25-008328 |
| Operating Margin | -17% | Operating Income / Revenue | OK | 0001683168-26-006340, 0001683168-25-008328 |
| ROIC | -34.25% | NOPAT / Average Invested Capital | OK | 0001683168-26-006340, 0001683168-25-008328 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001683168-26-006340 |
| Current Ratio | 5.46x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001683168-26-002644 |